Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis
Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis
复制标题
DOI：
10.1371/journal.pone.0217263
复制
发表时间：
2019-07-10
期刊：
影响因子：
3.7
通讯作者：
Paredes, Angelo H.
中科院分区：
文献类型：
--
作者：
Kar, Sumit;Paglialunga, Sabina;Paredes, Angelo H.
非酒精性脂肪性肝炎（NASH）是一种慢性肝病，可导致肝硬化，肝移植，甚至肝细胞癌。虽然肝活检仍然是疾病诊断的参考标准，但NASH的非侵入性可溶性生物标志物的分析和临床开发对于推进该领域具有重要意义。为此，我们对一系列涉及肝脏炎症的促炎细胞因子和趋化因子进行了分析和临床验证; IL-6、CRP、TNF α、MCP-1、MIP-1 β、嗜酸性粒细胞趋化因子、VCAM-1。验证了生物标志物测定的准确度和精密度。在随机抽取的52例经活检证实的NAFLD/NASH患者中评价了临床性能。患者根据其纤维化分期分为三组：晚期（F3-F4）、轻度（F1-2）和无（F0）纤维化。晚期纤维化患者血清IL-6升高（2.71 pg/mL; 1.26 pg/mL; 1.39 pg/mL，p < 0.05），
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that can lead to cirrhosis, liver transplant, and even hepatocellular carcinoma. While liver biopsy remains the reference standard for disease diagnosis, analytical and clinical development of non-invasive soluble biomarkers of NASH are of great importance to advance the field. To this end, we performed analytical and clinical validation on a series of pro-inflammatory cytokines and chemokines implicated hepatic inflammation; IL-6, CRP, TNF alpha, MCP-1, MIP-1 beta, eotaxin, VCAM-1. Biomarker assays were validated for accuracy and precision. Clinical performance was evaluated in a random sample of 52 patients with biopsy-proven NAFLD/NASH. Patients were categorized into three groups according to their fibrosis stage; advanced (F3-F4), mild (F1-2) and no (F0) fibrosis. Serum IL-6 was increased in patients with advanced fibrosis (2.71 pg/mL; 1.26 pg/mL; 1.39 pg/mL p